These findings could potentiate a combined therapy using anti-PD-1 or anti-PD-L1 antibodies and the current standard therapies against leishmaniasis, which could be particularly important for diffuse cutaneous leishmaniasis treatment, a disease that is refractory to conventional treatment. Here, PDCD1 is linked to diffuse cutaneous Leishmaniasis.